Home LiteratureArticle Details
PMID: 3700607 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Relationships between alternative complement pathway activation, C-reactive protein, and pneumococcal infection.

Journal of clinical microbiology ·Vol. 23 ·No. 1 ·1986-01-00 ·Pages 56-61

Rabinovitch RA, Koethe SM, Kalbfleisch JH, Preheim LC, Rytel MW

Abstract

In the absence of specific antibody, opsonization of Streptococcus pneumoniae may be mediated by the alternative complement pathway (AP) or by C-reactive protein (CRP) via C1 binding. To determine the role of these mechanisms in pneumococcal (PNC) disease, we studied 19 patients with differing severities of PNC infection. C4 and CRP levels and zymosan-induced consumption of 50% hemolytic complement (CH50) were measured in specimens obtained acutely and then weekly. In patients with complicated illness, the modified mean CH50 in acute sera was 178 +/- 57 U/ml, significantly lower than the mean CH50 of 331 +/- 80 U/ml in patients with uncomplicated illness (P less than 0.05). The values of the two groups on a given day approximated each other on days 7, 14, and 23. Consumption of complement by zymosan was also lower in acute sera of patients with complicated illness, with a mean value of 19 +/- 18 U/ml compared with 58 +/- 30 U/ml in those with uncomplicated illness (P less than 0.05). This difference was also seen on day 7 (P less than 0.05). Disease involving lower-numbered PNC serotypes (less than 10) correlated with reduced availability of AP factors in acute sera, independent of illness severity. Mean CRP levels were inversely related to zymosan-induced complement activation in patients with complicated illness. These data suggest that in vivo depletion of AP factors is significantly greater in patients with complicated illness and is associated with high CRP levels. CRP may enhance AP activation via C3 convertase generation and function with it as a preantibody host defense mechanism.

MeSH Terms
Adult Aged C-Reactive Protein/analysis Complement Activation Complement C4/analysis Complement Pathway, Alternative Female Humans Male Meningitis, Pneumococcal/immunology Middle Aged Otitis Media/etiology,immunology Pneumococcal Infections/immunology Pneumonia, Pneumococcal/immunology Sepsis/immunology Zymosan/pharmacology
Chemicals
Complement C4 C-Reactive Protein Zymosan
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Rabinovitch R A
Koethe S M
Kalbfleisch J H
Preheim L C
Rytel M W
References (29)
29 references, click to expand
  1. The host response to invasion by Streptococcus pneumoniae: protection and the pathogenesis to tissue damage.
    Rev Infect Dis. 1981 Mar-Apr;3(2):282-8 PMID: 7020045
  2. PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA.
    Ann Intern Med. 1964 May;60:759-76 PMID: 14156606
  3. The fixation of C3b to pneumococcal cell wall polymers as a result of activation of the alternative complement pathway.
    J Immunol. 1981 Oct;127(4):1287-9 PMID: 7024404
  4. Inhibitory effect of C-reactive protein on alternative C pathway activation by liposomes and Streptococcus pneumoniae.
    J Immunol. 1981 Nov;127(5):2089-92 PMID: 6913608
  5. Heat labile opsonins to Pneumococcus. 3. The participation of immunoglobulin and of the alternate pathway of C3 activation.
    J Immunol. 1972 Jun;108(6):1681-9 PMID: 4402312
  6. C3 shunt activation in human serum chelated with EGTA.
    J Immunol. 1972 Oct;109(4):807-9 PMID: 4627510
  7. Correlation of circulating capsular polysaccharide with bacteremia in pneumococcal pneumonia.
    Infect Immun. 1972 Oct;6(4):431-7 PMID: 4628896
  8. The role of immunoglobulin in the interaction of pneumococci and the properdin pathway: evidence for its specificity and lack of requirement for the Fc portion of the molecule.
    J Immunol. 1974 May;112(5):1635-42 PMID: 4150446
  9. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin.
    J Immunol. 1974 Jun;112(6):2135-47 PMID: 4151108
  10. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q.
    J Immunol. 1974 Jul;113(1):9-17 PMID: 4208926
  11. Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era.
    Arch Intern Med. 1974 Sep;134(3):505-10 PMID: 4152800
  12. Possible pathogenetic role of capsular antigens in fulminant pneumococcal disease with disseminated intravascular coagulation (DIC).
    Am J Med. 1974 Dec;57(6):889-96 PMID: 4139894
  13. Pneumococcal type-associated variability in alternate complement pathway activation.
    Infect Immun. 1975 Oct;12(4):772-8 PMID: 329
  14. The role of the capsular polysaccharide in the activation of the alternative pathway by the pneumococcus.
    J Immunol. 1976 Feb;116(2):367-70 PMID: 2634
  15. Antigenemia in fulminant pneumococcemia.
    Ann Intern Med. 1976 May;84(5):561-3 PMID: 5936
  16. Complement system in pneumococcal infections.
    Infect Immun. 1976 Apr;13(4):1120-5 PMID: 1279001
  17. Activation of the alternative pathway by pneumococcal cell walls.
    J Immunol. 1977 Feb;118(2):451-4 PMID: 14211
  18. Interactions of C-reactive protein with the first component of human complement.
    J Immunol. 1977 Jul;119(1):187-92 PMID: 17637
  19. Classical and alternative complement pathway activation by pneumococci.
    Infect Immun. 1977 Aug;17(2):296-302 PMID: 19357
  20. Complement levels in pneumococcal pneumonia.
    Infect Immun. 1977 Oct;18(1):14-22 PMID: 20405
  21. Opsonic requirements for phagocytosis of Streptococcus pneumoniae types VI, XVIII, XXIII, and XXV.
    Infect Immun. 1977 Nov;18(2):291-7 PMID: 21849
  22. Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid.
    J Immunol. 1978 Jan;120(1):174-8 PMID: 24071
  23. The effect of complement depletion on lung clearance of bacteria.
    J Clin Invest. 1978 Aug;62(2):373-8 PMID: 27534
  24. Kinetic assessment of alternative complement pathway activity in a hemolytic system. II. Influence of antibody on alternative pathway activation.
    J Immunol. 1978 Jul;121(1):371-6 PMID: 670706
  25. Efficacy of antimicrobial therapy in experimental rat pneumonia: effects of impaired phagocytosis.
    Infect Immun. 1979 Jul;25(1):366-75 PMID: 478640
  26. Complement fragments, alveolar macrophages, and alveolitis.
    Am J Pathol. 1979 Oct;97(1):93-110 PMID: 495697
  27. Activation of C3 via the alternative complement pathway results in fixation of C3b to the pneumococcal cell wall.
    J Immunol. 1980 May;124(5):2502-6 PMID: 7365262
  28. Complement in pneumococcal infections with varying degrees of severity.
    Scand J Infect Dis. 1981;13(4):263-8 PMID: 7313580
  29. The role of complement in the host's defense against Streptococcus pneumoniae.
    Rev Infect Dis. 1981 Mar-Apr;3(2):289-98 PMID: 7020046
Article Info
Journal
Journal of clinical microbiology
Abbr.
J Clin Microbiol
ISSN
0095-1137
Published
1986-01-00
Pages
56-61
Language
English
Region
United States
NLM ID
7505564
PMCID
PMC268572
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]